Arvinas Stock Price, News & Analysis

On April 5, 2021, Arvinas, a clinical-stage biotechnology company, announced two presentations at the AACR Annual Meeting 2021, focusing on its PROTAC degraders, ARV-110 and ARV-471. These presentations will be held virtually from April 10-15, 2021, and May 17-21, 2021.

ARV-110 targets metastatic castration-resistant prostate cancer, while ARV-471 is aimed at ER+/HER2- breast cancer. Both presentations are scheduled for April 11, 2021, delivered by Dr. Lawrence B. Snyder. Abstracts will be available on the AACR website starting April 9, 2021.

Arvinas, a clinical-stage biotechnology company focused on targeted protein degradation, will participate in two virtual investor conferences. Dr. John Houston, President and CEO, will speak at the Guggenheim Targeted Protein Degradation Day on March 16, 2021, and at the 33rd Annual Roth Conference on March 17, 2021. Both panel discussions will be accessible via live audio webcasts on Arvinas’ website, with replays available for 30 days. Arvinas is advancing therapies using its PROTAC® platform to address life-threatening diseases, including prostate and breast cancers.

Arvinas, a clinical-stage biopharmaceutical company, reported its financial results for Q4 and the full year ended December 31, 2020. The company raised $431.9 million from a public stock offering, closing with $688.5 million in cash and equivalents. Q4 revenues decreased to $2.2 million from $4.9 million year-over-year, while total revenue for 2020 was $21.8 million, down from $43.0 million in 2019. A net loss expanded to $41.5 million in Q4, totaling $119.3 million for the year. However, the company noted significant clinical progress in its ARV-471 and ARV-110 programs.

Arvinas, a clinical-stage biopharmaceutical company, announced that its President and CEO, John Houston, and Chief Scientific Officer, Ian Taylor, will participate in a fireside chat at the Guggenheim Healthcare Talks: 2021 Oncology Day on February 11 at 4:30 p.m. ET. The event will be accessible via a live audio webcast on Arvinas’ website. The company focuses on developing innovative therapies that target disease-causing proteins, with ongoing clinical programs for ARV-110 and ARV-471 aimed at treating advanced forms of prostate and breast cancer respectively.

Arvinas, Inc. (Nasdaq: ARVN) announced the full exercise of the underwriter's option to purchase additional shares in its recent public offering, resulting in a total sale of 6,571,428 shares. This offering has generated approximately $431.9 million in net proceeds. Goldman Sachs & Co. LLC and Piper Sandler & Co. managed the offering, with additional support from Cantor Fitzgerald & Co. and BMO Capital Markets. The press release clarifies this is not an offer to sell or solicit any securities unlawfully.

Arvinas, Inc. (Nasdaq: ARVN) has priced a public offering of 5,714,286 shares of its common stock at $70.00 per share, with an option for underwriters to purchase an additional 857,142 shares. This offering is expected to close around December 18, 2020, subject to standard conditions. The funds raised will support Arvinas' efforts in developing targeted protein degradation therapies through its PROTAC® platform, which focuses on treating severe diseases. Goldman Sachs and Piper Sandler are leading the underwriting process.

Arvinas, Inc. (Nasdaq: ARVN) has announced a public offering of $250 million of its common stock, with an additional $37.5 million option for underwriters. Goldman Sachs & Co. LLC and Piper Sandler & Co. are the joint book-running managers. This offering is part of a planned strategy to support Arvinas’ ongoing clinical programs, including its two key candidates: ARV-110 for prostate cancer and ARV-471 for breast cancer. The offering is subject to market conditions and investor interest.

Arvinas, a clinical-stage biopharmaceutical company, announced clinical updates on its PROTAC® protein degraders: ARV-471 and ARV-110. ARV-471 shows potential for best-in-class safety and efficacy in patients with ER+/HER2- breast cancer, demonstrated by a 42% clinical benefit rate and confirmed partial responses. ARV-110 displays anti-tumor activity in men with metastatic castration-resistant prostate cancer, achieving a 40% PSA50 response rate. Both compounds are well tolerated, with ongoing trials expected to advance in 2021, including combination studies.

Arvinas, a clinical-stage biotechnology company, will host a live webcast on December 14, 2020, at 8:00 a.m. ET to present updates on its clinical programs for ARV-471 and ARV-110. The presentation will cover the Phase 1 dose escalation studies for ARV-471 in ER positive/HER2 negative breast cancer and ARV-110 for metastatic castrate-resistant prostate cancer, along with details about the newly initiated Phase 2 dose expansion study for ARV-110.